{"title":"小儿难治性实体瘤的剂量化疗:单中心回顾性研究","authors":"Yukari Sakurai, Fuminori Iwasaki, Ayana Hirose, Naoya Matsumoto, Naoyuki Miyagawa, Dai Keino, Tomoko Yokosuka, Satoshi Hamanoue, Masakatsu Yanagimachi, Masae Shiomi, Shoko Goto, Mio Tanaka, Yukichi Tanaka, Kumiko Nozawa, Hiroaki Goto","doi":"10.1097/mph.0000000000002870","DOIUrl":null,"url":null,"abstract":"Metronomic chemotherapy (MC) is based on chronic administration of chemotherapeutic agents at minimally toxic doses without prolonged drug-free breaks, that inhibits tumor angiogenesis and induces tumor dormancy. This study aimed to determine the efficacy of MC for pediatric refractory solid tumors. We retrospectively analyzed the data of pediatric patients with relapsed/refractory solid tumors who received treatment, including low-dose continuous administration of anticancer drugs, at our institute. Of the 18 patients, the disease statuses at the initiation of MC were complete remission (n=2), partial remission/stable disease (n=5), and progressive disease (n=11). The overall survival rate was 61% at 12 months and 34% at 24 months, and the progression-free survival rate was 21% at 12 and 24 months. Although only 5 of the 18 patients showed certain tumor regression or maintained remission, tumors that stabilized, maintained remission/stable disease, and showed certain advantages in terms of overall survival rate, even if limited to progressive disease. Approximately half of the patients demonstrated temporal tumor stabilization and improved survival time. Overall, previous reports and the present study support the conclusion that MC has the potential to play an important role in pediatric cancer treatment during the advanced stage.","PeriodicalId":16693,"journal":{"name":"Journal of Pediatric Hematology/Oncology","volume":null,"pages":null},"PeriodicalIF":0.9000,"publicationDate":"2024-04-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Metronomic Chemotherapy for Pediatric Refractory Solid Tumors: A Retrospective Single-Center Study.\",\"authors\":\"Yukari Sakurai, Fuminori Iwasaki, Ayana Hirose, Naoya Matsumoto, Naoyuki Miyagawa, Dai Keino, Tomoko Yokosuka, Satoshi Hamanoue, Masakatsu Yanagimachi, Masae Shiomi, Shoko Goto, Mio Tanaka, Yukichi Tanaka, Kumiko Nozawa, Hiroaki Goto\",\"doi\":\"10.1097/mph.0000000000002870\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Metronomic chemotherapy (MC) is based on chronic administration of chemotherapeutic agents at minimally toxic doses without prolonged drug-free breaks, that inhibits tumor angiogenesis and induces tumor dormancy. This study aimed to determine the efficacy of MC for pediatric refractory solid tumors. We retrospectively analyzed the data of pediatric patients with relapsed/refractory solid tumors who received treatment, including low-dose continuous administration of anticancer drugs, at our institute. Of the 18 patients, the disease statuses at the initiation of MC were complete remission (n=2), partial remission/stable disease (n=5), and progressive disease (n=11). The overall survival rate was 61% at 12 months and 34% at 24 months, and the progression-free survival rate was 21% at 12 and 24 months. Although only 5 of the 18 patients showed certain tumor regression or maintained remission, tumors that stabilized, maintained remission/stable disease, and showed certain advantages in terms of overall survival rate, even if limited to progressive disease. Approximately half of the patients demonstrated temporal tumor stabilization and improved survival time. Overall, previous reports and the present study support the conclusion that MC has the potential to play an important role in pediatric cancer treatment during the advanced stage.\",\"PeriodicalId\":16693,\"journal\":{\"name\":\"Journal of Pediatric Hematology/Oncology\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":0.9000,\"publicationDate\":\"2024-04-29\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Pediatric Hematology/Oncology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1097/mph.0000000000002870\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"HEMATOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Pediatric Hematology/Oncology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1097/mph.0000000000002870","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"HEMATOLOGY","Score":null,"Total":0}
引用次数: 0
摘要
周期性化疗(MC)是指以最小毒性剂量长期服用化疗药物,不延长无药间歇期,从而抑制肿瘤血管生成并诱导肿瘤休眠。本研究旨在确定 MC 治疗小儿难治性实体瘤的疗效。我们回顾性分析了在我院接受治疗的复发性/难治性实体瘤儿科患者的数据,包括小剂量连续给药抗癌药物。在18名患者中,开始接受MC治疗时的疾病状态分别为完全缓解(2人)、部分缓解/疾病稳定(5人)和疾病进展(11人)。12个月和24个月的总生存率分别为61%和34%,12个月和24个月的无进展生存率分别为21%。虽然18名患者中只有5名出现了一定的肿瘤消退或维持缓解,但肿瘤稳定、维持缓解/病情稳定的患者,即使仅限于进展期疾病,在总生存率方面也显示出一定的优势。约半数患者的肿瘤在时间上趋于稳定,生存时间也有所改善。总之,以往的报告和本研究都支持 MC 有可能在儿童癌症晚期治疗中发挥重要作用这一结论。
Metronomic Chemotherapy for Pediatric Refractory Solid Tumors: A Retrospective Single-Center Study.
Metronomic chemotherapy (MC) is based on chronic administration of chemotherapeutic agents at minimally toxic doses without prolonged drug-free breaks, that inhibits tumor angiogenesis and induces tumor dormancy. This study aimed to determine the efficacy of MC for pediatric refractory solid tumors. We retrospectively analyzed the data of pediatric patients with relapsed/refractory solid tumors who received treatment, including low-dose continuous administration of anticancer drugs, at our institute. Of the 18 patients, the disease statuses at the initiation of MC were complete remission (n=2), partial remission/stable disease (n=5), and progressive disease (n=11). The overall survival rate was 61% at 12 months and 34% at 24 months, and the progression-free survival rate was 21% at 12 and 24 months. Although only 5 of the 18 patients showed certain tumor regression or maintained remission, tumors that stabilized, maintained remission/stable disease, and showed certain advantages in terms of overall survival rate, even if limited to progressive disease. Approximately half of the patients demonstrated temporal tumor stabilization and improved survival time. Overall, previous reports and the present study support the conclusion that MC has the potential to play an important role in pediatric cancer treatment during the advanced stage.
期刊介绍:
Journal of Pediatric Hematology/Oncology (JPHO) reports on major advances in the diagnosis and treatment of cancer and blood diseases in children. The journal publishes original research, commentaries, historical insights, and clinical and laboratory observations.